Allyx Therapeutics
Business Services · Connecticut, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
555 Long Wharf Dr Ste 11, New Haven, Con...Phone Number
(203) 855-0400Website
www.allyxthera.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Allyx Therapeutics
Allyx Therapeutics is focused on developing an oral drug, ALX-001, aimed at reversing learning and memory deficits associated with Alzheimer's disease. The company is dedicated to preserving and protecting synapses for individuals affected by neurodegenerative diseases. Their research also extends to Parkinson's disease, with ongoing clinical studies to evaluate the efficacy of their lead candidate. Allyx Therapeutics targets patients suffering from neurodegenerative conditions, seeking innovative solutions to improve their quality of life.Explore more
Allyx Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Allyx Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Allyx Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Allyx Therapeutics had a recent Job posting/layoffs
Check if Allyx Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Allyx Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Allyx Therapeutics launches new products
Earning: See what the market has to say on Allyx Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Allyx Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Allyx Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Allyx Therapeutics
Compare insights from companies similar to Allyx Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Allyx Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Allyx Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Allyx Therapeutics.
Allyx Therapeutics financials insights
Gather financial insights about Allyx Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$26.4M
Allyx Therapeutics Tech Stack
A closer look at the technologies used by Allyx Therapeutics
Most Recent Scoops
Funding
Funding
Funding
Project
Spending/Investment, Funding
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Event
Allyx Therapeutics News & Media
Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001
Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical studyAllyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Allyx Therapeutics
Sign Up For FreeTo access detailed company insights
Allyx Therapeutics is focused on developing an oral drug, ALX-001, aimed at reversing learning and memory deficits associated with Alzheimer's disease. The company is dedicated to preserving and protecting synapses for individuals affected by neurodegenerative diseases. Their research also extends to Parkinson's disease, with ongoing clinical studi... Read More
